Scott Reznik, M.D.
Dr. Scott Reznik is a thoracic surgeon who specializes in minimally invasive surgery at the UT Southwestern Medical Center and the Harold C. Simmons Comprehensive Cancer Center in Dallas, Texas. He has special expertise in surgical treatment for problems of the chest, including both benign and malignant diseases of the lungs, esophagus, and mediastinum and malignant pleural mesothelioma.[1]
Dr. Reznik is skilled in minimally invasive techniques that help most patients recover faster and return to their lives more quickly and robotic surgery techniques involving small instruments inserted through tiny incisions and controlled through a computer console.
Dr. Reznik strongly believes that treatment decisions should be made in consultation with patients and their families. He actively engages with them to ensure that their care plan is customized to their goals and needs.[1]
Education and Career
Dr. Reznik attended Duke University for his undergraduate education. After graduating with a degree in Chemistry, he went on to earn his medical degree from Washington University School of Medicine in St. Louis. Dr. Reznik stayed in St. Louis for an internship and residency at Washington University/Barnes-Jewish Hospital. He also completed a postdoctoral research fellowship there in Lung Transplant Immunology and went on to complete advanced training in Thoracic and Cardiovascular Surgery at the Cleveland Clinic. He is board-certified by the American Board of Surgery and the American Board of Thoracic Surgery.[1]
Following completion of his education and training, Dr. Reznik served as Chief of Thoracic Surgery at Schott and White Memorial Hospital and Clinic in Temple, Texas.
Professional Memberships
- General Thoracic Surgical Club
- American College of Surgeons
- Association for Academic Surgery
- Society of Thoracic Surgeons
Research
Dr. Reznik’s research interests include lung cancer, esophageal cancer, and minimally invasive surgical approaches for all types of thoracic malignancies. He has a special interest in patient safety and quality care, including research on the best and safest way to educate surgical trainees.[1]
His most recent research includes:[2]
Defining Volume Targets for Regionalization of Pancreaticoduodenectomy, Esophagectomy, and Major Lung Resection Centers to Improve Oncologic and Surgical Outcomes. Ju, M. R., Karalis, J. D., Leonard, G., Mansour, J. C., Karagkounis, G., Wang, S. C., Reznik, S. I. & Porembka, M. R., Jan 2024, In Annals of Surgical Oncology. 31, 1, p. 499-513 15 p.
Esophageal and Esophagogastric Junction Cancers, Version 2.2023. Ajani, J. A., D’Amico, T. A., Bentrem, D. J., Cooke, D., Corvera, C., Das, P., Enzinger, P. C., Enzler, T., Farjah, F., Gerdes, H., Gibson, M., Grierson, P., Hofstetter, W. L., Ilson, D. H., Jalal, S., Keswani, R. N., Kim, S., Kleinberg, L. R., Klempner, S., Lacy, J., & 22 others, Apr 2023, In: JNCCN Journal of the National Comprehensive Cancer Network. 21, 4, p. 393-422 30 p.
Life-threatening hemoptysis in patients with metastatic kidney cancer. Patel, V. M., Elias, R., Asokan, A., Sharma, A., Christie, A., Pedrosa, I., Chiu, H., Reznik, S., Hannan, R., Timmerman, R. & Brugarolas, J., Aug 2023, In: Clinical Genitourinary Cancer. 21, 4, p. 497-506 10 p.
Serum Interleukin 6 Level is Associated with Overall Survival and Treatment Response in Gastric and Gastroesophageal Junction Cancer. Karalis, J. D., Ju, M. R., Yoon, L. Y., Castro-Dubon, E. C., Reznik, S. I., Hammer, S. T. G., Porembka, M. R. & Wang, S. C., Dec 1, 2023, In Annals of surgery. 278, 6, p. 918-924 7 p.
Commentary: Leave the Knife and Take the Needle and a Cytopathologist. Reznik, S. I., Sep 1, 2022, In Seminars in thoracic and cardiovascular surgery. 34, 3, p. 1111-1112 2 p. Gastric Cancer, Version 2.2022. Ajani, J. A., D’Amico, T. A., Bentrem, D. J., Chao, J., Cooke, D., Corvera, C., Das, P., Enzinger, P. C., Enzler, T., Fanta, P., Farjah, F., Gerdes, H., Gibson, M. K., Hochwald, S., Hofstetter, W. L., Ilson, D. H., Keswani, R. N., Kim, S., Kleinberg, L. R., Klempner, S. J., & 21 others, Feb 2022, In: JNCCN Journal of the National Comprehensive Cancer Network. 20, 2, p. 167-192 26 p.
Lenvatinib inhibits the growth of gastric cancer patient-derived xenografts generated from a heterogeneous population. Karalis, J. D., Yoon, L. Y., Hammer, S. T. G., Hong, C., Zhu, M., Nassour, I., Ju, M. R., Xiao, S., Castro-Dubon, E. C., Agrawal, D., Suarez, J., Reznik, S. I., Mansour, J. C., Polanco, P. M., Yopp, A. C., Zeh, H. J., Hwang, T. H., Zhu, H., Porembka, M. R. & Wang, S. C., Dec 2022, In Journal of Translational Medicine. 20, 1, 116.
Multi-institutional Evaluation of a Debate-Style Journal Club for Cardiothoracic Surgery Trainees. Thoracic Education Cooperative Group (TECoG), Jul 2022, In Annals of Thoracic Surgery. 114, 1, p. 327-333 7 p.
